Multiple myeloma is one of the more stubborn blood cancers to treat. Patients often cycle through several lines of therapy before options run out, and finding something that works in those late stages, without causing serious side effects, remains one of oncology’s harder problems. That is the space C4 Therapeutics, Inc. (NASDAQ: CCCC) is trying to crack. The company has confirmed that clinical data for its lead drug candidate, cemsidomide, is being presented at the European Hematology Association 2026 Congress, one of the most closely watched gatherings in hematology research.
The data being presented comes from C4’s fully enrolled Phase 1 trial of cemsidomide in combination with dexamethasone for patients with relapsed or refractory multiple myeloma, meaning patients whose cancer has returned or stopped responding to prior treatment. Cemsidomide is what is known as an IKZF1/3 degrader, a type of molecule that works by enlisting the body’s own cellular machinery to destroy specific proteins that drive cancer growth. C4 calls this approach targeted protein degradation, and it forms the foundation of the company’s proprietary Degronimid platform.
The EHA Congress is not a minor venue. It draws leading hematologists and oncology researchers from around the world, and presenting data there carries real weight for clinical-stage companies. For C4, the timing adds an extra layer of interest. Just weeks earlier, Bristol-Myers Squibb Company (NYSE: BMY) reported positive Phase 3 data in multiple myeloma using a drug that works through the same general mechanism, validating the approach in a large, late-stage clinical trial.
What distinguishes cemsidomide, according to C4’s management, is its differentiated safety profile compared to earlier drugs in the same class. The company believes that distinction matters, particularly in a patient population that has already been through multiple rounds of treatment and may have limited tolerance for additional toxicity. The company has described the late-line myeloma space as a largely uncaptured market, and it is building its clinical case around the idea that a next-generation degrader with better tolerability could earn a meaningful place in the treatment landscape.
From a financial standpoint, C4 is not operating on fumes. The company reported $235 million in cash and Q1 2026 revenue of $6.15 million. For a clinical-stage company, that balance sheet provides meaningful runway as it works toward pivotal data expected in 2027, with global enrollment currently ongoing.
Beyond myeloma, C4 is also advancing CFT8919, a separate drug candidate targeting a specific mutation, known as EGFR L858R, found in certain non-small cell lung cancer patients. That program adds a second oncology track to the company’s pipeline and reflects C4’s broader ambition to apply its degradation platform across multiple cancer types.
As for the stock, CCCC has pulled back over the past five trading days, but it remains up approximately 98% year to date, a run driven in large part by the BMS-related catalyst in May and continued investor attention on the protein degradation space. The EHA presentation itself does not represent a regulatory milestone, but conference presentations at congresses of this caliber often shape how physicians and investors think about where a drug is headed.
The next major inflection point for C4 is its 2027 pivotal data readout. Between now and then, presentations like the one at EHA serve as checkpoints, opportunities for the company to show that the science is holding up and that the case for cemsidomide continues to build.
